Those among our colleagues, observers, and competitors who routinely follow this blog or our tweets at @hmpharmacon will probably wonder why we are not posting much concerning our THIRDSPACE patent knowledge management project. Well, the reason is that we are working hard on two fronts. One is acquiring, indexing and annotating the textual and chemical data for the ocular pharmacology pilot modul...

For decades the pharmaceutical industry has flourished on the discovery of new small molecule drugs. A paradigm change is now under way: as the best-selling drugs from the trailing end of this long-sustained wave of innovation loose their patent protection, they are not replaced to any extent that could be called sufficient – not economically, certainly not in terms of meeting of unmet medical ne...

Here are 9 remarkable international applications for life science patents that were published during the past month: wound hemostasis, metabolic syndrome, artificial glands and lymph nodes, malaria vaccines, oral coagulation factors for hemophila, brain cancer magnetotherapy, proliferative vitroretinopathy and rational methods for identifying regenerative tissue therapies are the focus areas. PLE...

You may have noticed that this blog now lists the three posts that have been most frequently accessed during the past 30 days. There is a quite satisfactory month-over month growth in overall visitors to this blog, and so I thought it might also be of interest to summarize some additional access statistics that span the past two years, from May 2009 to today.The post that generated most all-time ...

Today we present 11 new international patent applications from four focus fields: influenza vaccines (2), complement activation (2), addiction (3), and rare central nervous system diseases (4). As usual, all of these are not quite the run-of-the-mill type patent documents. PLEASE CITE AS : Mucke HAM. Patent Highlights for April 2011. Published online on the H.M. Pharma Consultancy Blog (URL:http:...

Cloud computing is helping H. M. Pharma Consultancy. Its also taking a slight toll on our resources because we keep getting questions whether the client-confidential data we keep or generate really are, well, secure?Recently the no-hassles file backup and synchronization service Dropbox modified its terms of use, and a discussion erupted that went all emotional and bitter. Much of it revolved ar...

Readers of this blog will know that H. M. Pharma Consultancy has always been an adamant advocate of using patents not only as strategic tools but also as an invaluable source of technical and scientific information. In the engineering and information technology there would be no need to stress this, but in medicine and the life sciences the“ Patents-Ugh!” attitude remains strong.Our little enterp...

Starting with this fourth edition of our monthly life science patent highlights, we link patent identifiers to the new version of Espacenet at http://t1.espacenet.com/. To facilitate navigation with the commentaries, title patents and their base data now carry a yellow marker .PLEASE CITE AS : Mucke HAM. Patent Highlights for March 2011. Published online on the H.M. Pharma Consultancy Blog (htt...

In early March I spent a week on Tenerife - doing a bit of enthnopharmacology research, relaxing a bit once and a while. (Easy to do if you have only slow wireless internet access) A note in a local newspaper caught my eye: reports of prehistoric aboriginal habitation in a ravine where archeologists had been working for eight months, digging and (good practice!) milking the locals for useful facts...

In Japan, there are already thousands confirmed dead in the aftermath of what will go down in history as the Great Sendai Quake. Many more thousands are still unaccounted for, hundreds of thousands have been displaced. There are not even estimates yet as to the trillions in direct property damage, and as for the Japanese economy...Against this background there is astounding news, and actually I re...